All posts by Aparna Raghu

Approving Trumenba: Why Not Bexsero?

DSC03308-C2-PURPLELast Wednesday, the FDA approved a vaccine for Meningitis B1,2, the same strain of bacterial meningitis that Princeton students faced last year. Yet the newly-approved drug is not Novartis’ Bexsero, which thousands of students at Princeton and UCSB have received in the past year. Instead, the FDA approved Pfizer’s Trumenba. This forces us to wonder why the FDA decided to approve Trumenba first, even though Bexsero has now been used safely and effectively in the United States and is approved in Canada, Europe, and Australia3.

The most straightforward explanation for the earlier approval of Trumenba is that Pfizer filed for approval before Novartis4. Continue reading Approving Trumenba: Why Not Bexsero?